Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, Poston J, Venkataraman G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Iris Lim H, Martin P, Cohen JB, Evens A, Al-Mansour Z, Singavi A, Fenske TS, Blum KA. Alinari L, et al. Among authors: park si. Am J Hematol. 2016 Jun;91(4):395-9. doi: 10.1002/ajh.24299. Am J Hematol. 2016. PMID: 26800311 Free PMC article.
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
Reddy NM, Greer JP, Morgan DS, Chen H, Park SI, Richards KL. Reddy NM, et al. Among authors: park si. Leukemia. 2017 Jan;31(1):241-244. doi: 10.1038/leu.2016.255. Epub 2016 Sep 22. Leukemia. 2017. PMID: 27654851 Free PMC article. Clinical Trial. No abstract available.
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD. Ujjani CS, et al. Among authors: park si. Blood. 2016 Nov 24;128(21):2510-2516. doi: 10.1182/blood-2016-06-718106. Epub 2016 Oct 3. Blood. 2016. PMID: 27697771 Free PMC article. Clinical Trial.
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.
Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Carson KR, et al. Among authors: park si. Cancer. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2. Cancer. 2017. PMID: 27911989 Free PMC article.
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB. Greenwell IB, et al. Among authors: park si. Cancer. 2018 Jun 1;124(11):2306-2315. doi: 10.1002/cncr.31328. Epub 2018 Mar 26. Cancer. 2018. PMID: 29579328 Free PMC article.
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D. Kelly KR, et al. Among authors: park si. Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6. Clin Cancer Res. 2018. PMID: 30082475 Free PMC article. Clinical Trial.
1,278 results